AUROPHARMAPharmaceuticals
Aurobindo Pharma Ltd — PE Ratio & Valuation Analysis
₹1304.40
+0.49%
Current P/E20.69xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E21.8x4.9% below avg
✅
34.9% Discount to Industry
AUROPHARMA P/E 20.69x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹59.81 | ₹1183 | 19.8x |
| 2024 | ₹54.16 | ₹1335 | 24.6x |
| 2023 | ₹32.90 | ₹1084 | 32.9x |
| 2022 | ₹45.19 | ₹438 | 9.7x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Aurobindo Pharma Ltd Valuation
Aurobindo Pharma Ltd (AUROPHARMA) currently trades at 20.69x earnings. The Pharmaceuticals sector average PE is 31.77x. AUROPHARMA is trading at a discount to peers — may indicate relative value. Historically, AUROPHARMA has traded at an average PE of 21.8x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
11.08%
Dividend Yield
0.33%
More on Aurobindo Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.